Market Overview:
The global skin cancer diagnostics and therapeutics market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of skin cancer, rising awareness about early diagnosis and treatment of skin cancer, and technological advancements in the field of diagnostics and therapeutics. The global market for skin cancer diagnostics is segmented on the basis of type into basal cell carcinoma, squamous cell carcinoma, and melanoma. The melanoma segment is expected to grow at the highest CAGR during the forecast period owing to its high mortality rate as compared to other types of skin cancers. On the basis of application, the global market for skin cancer diagnostics is segmented into hospitals, clinics, research centers, and others (including diagnostic laboratories). The hospitals segment is expected to account for a major share in terms revenue contribution during 2018-2030 owing rising prevalence rates for various types if cancers across different geographies coupled with increasing healthcare expenditure by governments worldwide.
Product Definition:
Skin cancer diagnostics and therapeutics are the methods used to detect and treat skin cancer. Skin cancer is a form of cancer that begins in the cells of the skin. It is the most common type of cancer in the United States. The importance of skin cancer diagnostics and therapeutics is that it can help to detect and treat skin cancers early, which can improve outcomes.
Basal Cell Carcinoma:
Basal cell carcinoma is a type of skin cancer that develops in the epidermis, the top layer of skin. The most common site for this form of cancer is the head, neck and upper extremities. Other sites include scalp, face, arms and legs. This type can develop into multiple tumors which may spread to other parts of the body including lymph nodes leading to widespread disease distribution.
Squamous Cell Carcinoma:
Squamous cell carcinoma is a type of skin cancer that develops from the squamous cells located in the epidermis. These cells are also known as keratinocytes and are essential for healthy skin functioning. SCCs account for approximately 10% of all cancers worldwide, with more than 90% of cases occurring in people over 60 years old.
Application Insights:
The market is segmented into hospital, clinic, cancer research center and others. The hospital application segment dominated the overall market in terms of revenue in 2017. This can be attributed to a high prevalence of skin cancer cases that require diagnostic evaluation at hospitals. For instance, as per the Skin Cancer Foundation statistics published in 2018, around 5 million people are diagnosed with skin cancer annually and around 1 million deaths occur due to this disease globally every year. In addition, increasing awareness about early diagnosis is boosting growth across the globe owing to which application centers are emerging as preferred destinations for patients with suspicious lesions or moles on their bodies (clinic).
However, clinics are expected to witness lucrative growth over the forecast period due to an increase in demand for non-invasive procedures along with advancements made by companies operating within this sector (cancer research centers).
Regional Analysis:
North America dominated the global skin cancer diagnostics and therapeutics market in 2017. This can be attributed to the presence of key players, high R&D investment by them, and availability of effective treatment methods for various types of skin cancers. In addition, rise in prevalence of basal cell carcinoma (BCC) is expected to drive regional growth over the forecast period. According to American Cancer Society’s 2018 estimates, around 72% cases were estimated to be BCC while 27% were squamous cell carcinoma (SCC). Thus rising prevalence is one major factor responsible for North America’s dominance in this space.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to increase government initiatives & programs coupled with rise awareness about early diagnosis & treatment methods especially for melanoma.
Growth Factors:
- Increasing incidence of skin cancer: The incidence of skin cancer is increasing at a rapid pace across the globe. This is primarily attributed to the changing lifestyle and growing awareness about the disease.
- Growing demand for early diagnosis and treatment: There is a growing demand for early diagnosis and treatment of skin cancer, as this helps in reducing the mortality rate associated with the disease.
- Technological advancements in diagnostics and therapeutics: There has been a significant advancement in diagnostics and therapeutics technologies for skin cancer in recent years, which is aiding in better detection and treatment of the disease.
- Rising funding for research on skin cancer: A large number of organizations are investing heavily in research on skin cancer, which is helping to improve our understanding about this disease.
Scope Of The Report
Report Attributes
Report Details
Report Title
Skin Cancer Diagnostics and Therapeutics Market Research Report
By Type
Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
By Application
Hospital, Clinic, Cancer Research Center, Others
By Companies
GlaxoSmithKline, Merck, Novartis, Pfizer, Qiagen, Roche, Sanofi, Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
122
Number of Tables & Figures
86
Customization Available
Yes, the report can be customized as per your need.
Global Skin Cancer Diagnostics and Therapeutics Market Report Segments:
The global Skin Cancer Diagnostics and Therapeutics market is segmented on the basis of:
Types
Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Cancer Research Center, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Qiagen
- Roche
- Sanofi
- Abbott
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
Highlights of The Skin Cancer Diagnostics and Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Basal Cell Carcinoma
- Squamous Cell Carcinoma
- Melanoma
- By Application:
- Hospital
- Clinic
- Cancer Research Center
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Skin Cancer Diagnostics and Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Skin cancer diagnostics and therapeutics is the study of how to diagnose and treat skin cancers.
Some of the major players in the skin cancer diagnostics and therapeutics market are GlaxoSmithKline, Merck, Novartis, Pfizer, Qiagen, Roche, Sanofi, Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly.
The skin cancer diagnostics and therapeutics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Skin Cancer Diagnostics and Therapeutics Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Skin Cancer Diagnostics and Therapeutics Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Skin Cancer Diagnostics and Therapeutics Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Skin Cancer Diagnostics and Therapeutics Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Skin Cancer Diagnostics and Therapeutics Market Size & Forecast, 2020-2028 4.5.1 Skin Cancer Diagnostics and Therapeutics Market Size and Y-o-Y Growth 4.5.2 Skin Cancer Diagnostics and Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Basal Cell Carcinoma
5.2.2 Squamous Cell Carcinoma
5.2.3 Melanoma
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Cancer Research Center
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Skin Cancer Diagnostics and Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Skin Cancer Diagnostics and Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Basal Cell Carcinoma
9.6.2 Squamous Cell Carcinoma
9.6.3 Melanoma
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Cancer Research Center
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Basal Cell Carcinoma
10.6.2 Squamous Cell Carcinoma
10.6.3 Melanoma
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Cancer Research Center
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Basal Cell Carcinoma
11.6.2 Squamous Cell Carcinoma
11.6.3 Melanoma
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Cancer Research Center
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Basal Cell Carcinoma
12.6.2 Squamous Cell Carcinoma
12.6.3 Melanoma
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Cancer Research Center
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Basal Cell Carcinoma
13.6.2 Squamous Cell Carcinoma
13.6.3 Melanoma
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Cancer Research Center
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Skin Cancer Diagnostics and Therapeutics Market: Competitive Dashboard
14.2 Global Skin Cancer Diagnostics and Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline
14.3.2 Merck
14.3.3 Novartis
14.3.4 Pfizer
14.3.5 Qiagen
14.3.6 Roche
14.3.7 Sanofi
14.3.8 Abbott
14.3.9 AstraZeneca
14.3.10 Bristol-Myers Squibb
14.3.11 Eli Lilly